FDA approved Imbruvica (ibrutinib) for pediatric patients 1 year of age or older with chronic graft versus host disease after failure of 1 or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension.
The Lilabean Foundation for Pediatric Brain Cancer Research raised $900,000 at its 13th Annual Lilabean Foundation Fall Ball, held on Saturday, November 2. Proceeds from the Fall Ball will directly fund groundbreaking research initiatives focused on discovering new treatments and improving survival rates for children fighting pediatric brain cancer.
